Suppr超能文献

膀胱乳头状尿路上皮癌的组织学分级:1998年世界卫生组织/国际泌尿病理学会分类系统的预后价值及与传统分级系统的比较

Histological grading of papillary urothelial carcinoma of the bladder: prognostic value of the 1998 WHO/ISUP classification system and comparison with conventional grading systems.

作者信息

Oosterhuis J W A, Schapers R F M, Janssen-Heijnen M L G, Pauwels R P E, Newling D W, ten Kate F

机构信息

Department of Pathology, Stichting Ziekenhuizen Noord-Limburg, PO Box 1926, 5900 BX, Venlo, The Netherlands.

出版信息

J Clin Pathol. 2002 Dec;55(12):900-5. doi: 10.1136/jcp.55.12.900.

Abstract

AIM

To test the prognostic value of the 1998 WHO/ISUP (World Health Organisation/International Society of Urologic Pathology) consensus classification system in Ta papillary urothelial neoplasms of the bladder.

METHODS

The histological slides of 322 patients with a primary Ta tumour were classified according to the consensus classification system, and recurrence free survival (RFS) and progression free survival (PFS) were assessed for a mean follow up period of 79 months. In the same patient group, the RFS and PFS rates for the 1973 WHO grading system and a low grade/high grade system were analysed.

RESULTS

Recurrent tumours were seen in all categories of the 1998 WHO/ISUP classification system and five year RFS was not significantly different between the groups (p = 0.12). The five year PFS showed a small but significant difference (p = 0.04) between papillary neoplasms of low malignant potential (PNLMP) and high grade papillary urothelial carcinomas (HGPUCs). In the 1973 WHO classification, no significant difference was found in RFS and PFS between the different grades. In the low grade/high grade classification PFS was significantly better for low grade tumours (p = 0.01).

CONCLUSION

The prognostic value of the 1998 WHO/ISUP classification system is limited to predicting PFS, especially between PNLMP and HGPUC. The prognostic value of this system over other grading systems is questionable.

摘要

目的

检验1998年世界卫生组织/国际泌尿病理学会(WHO/ISUP)共识分类系统对膀胱Ta期乳头状尿路上皮肿瘤的预后价值。

方法

根据共识分类系统对322例原发性Ta期肿瘤患者的组织学切片进行分类,并评估其无复发生存期(RFS)和无进展生存期(PFS),平均随访期为79个月。在同一患者组中,分析了1973年WHO分级系统和低级别/高级别系统的RFS和PFS率。

结果

在1998年WHO/ISUP分类系统的所有类别中均可见复发性肿瘤,各组间五年RFS无显著差异(p = 0.12)。五年PFS在低恶性潜能乳头状肿瘤(PNLMP)和高级别乳头状尿路上皮癌(HGPUC)之间显示出微小但显著的差异(p = 0.04)。在1973年WHO分类中,不同级别之间的RFS和PFS无显著差异。在低级别/高级别分类中,低级别肿瘤的PFS明显更好(p = 0.01)。

结论

1998年WHO/ISUP分类系统的预后价值仅限于预测PFS,尤其是在PNLMP和HGPUC之间。该系统相对于其他分级系统的预后价值值得怀疑。

相似文献

6
Cancer heterogeneity and its biologic implications in the grading of urothelial carcinoma.
Cancer. 2000 Apr 1;88(7):1663-70. doi: 10.1002/(sici)1097-0142(20000401)88:7<1663::aid-cncr21>3.0.co;2-8.
9
Papillary urothelial neoplasm of low malignant potential: reliability of diagnosis and outcome.
BJU Int. 2004 Jun;93(9):1228-31. doi: 10.1111/j.1464-410X.2004.04848.x.

引用本文的文献

1
PLAP expression is linked to invasive tumor growth in urothelial carcinoma of the bladder.
Int Urol Nephrol. 2025 May;57(5):1381-1388. doi: 10.1007/s11255-024-04319-8. Epub 2024 Dec 16.
3
Tumour Behaviour of Low-Grade Papillary Urothelial Carcinoma: A Single-Centre Retrospective Study.
Cureus. 2021 Jun 29;13(6):e16012. doi: 10.7759/cureus.16012. eCollection 2021 Jun.
4
ARID1A upregulation predicts better survival in patients with urothelial bladder carcinoma.
J Int Med Res. 2020 Apr;48(4):300060519895687. doi: 10.1177/0300060519895687. Epub 2019 Dec 31.
8
Role of morphometry and proliferative parameters in grading of urothelial neoplasms.
Cent European J Urol. 2015;68(1):37-44. doi: 10.5173/ceju.2015.01.447. Epub 2015 Mar 13.

本文引用的文献

4
Long-term follow-up of noninvasive bladder tumours (stage Ta): recurrence and progression.
BJU Int. 2000 May;85(7):824-8. doi: 10.1046/j.1464-410x.2000.00547.x.
5
Cancer heterogeneity and its biologic implications in the grading of urothelial carcinoma.
Cancer. 2000 Apr 1;88(7):1663-70. doi: 10.1002/(sici)1097-0142(20000401)88:7<1663::aid-cncr21>3.0.co;2-8.
6
World Health Organization and International Society of Urological Pathology classification and two-number grading system of bladder tumors.
Cancer. 2000 Apr 1;88(7):1509-12. doi: 10.1002/(sici)1097-0142(20000401)88:7<1509::aid-cncr1>3.0.co;2-g.
9
Diagnosis and grading of bladder cancer and associated lesions.
Urol Clin North Am. 1999 Aug;26(3):493-507. doi: 10.1016/s0094-0143(05)70197-x.
10
Bladder. Risk and prognostic factors--a pathologist's perspective.
Urol Clin North Am. 1999 Aug;26(3):481-92. doi: 10.1016/s0094-0143(05)70196-8.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验